IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes (Q43047523)

From Wikidata

Jump to navigation Jump to search

scientific article published on 16 December 2011

Language	Label	Description	Also known as
English	IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes	scientific article published on 16 December 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Hepatitis C virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Stephanie Bibert

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

23

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Pierre-Yves Bochud

object named as

Pierre-Yves Bochud

1

0 references

object named as

Markus H Heim

11

0 references

Bertrand Nalpas

object named as

Bertrand Nalpas

6

0 references

Darius Moradpour

object named as

Darius Moradpour

12

0 references

Thierry Poynard

object named as

Thierry Poynard

21

0 references

Jean-François Dufour

object named as

Jean-François Dufour

25

0 references

Zoltán Kutalik

3

object named as

Zoltán Kutalik

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

24

object named as

Stanislas Pol

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Gladys Martinetti

18

object named as

Gladys Martinetti

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

author name string

Julien Guergnon

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Nicolas Goossens

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Lorenz Kuske

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Beat Müllhaupt

9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Tillman Gerlach

10

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Andreas Cerny

13

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Raffaele Malinverni

14

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Stephan Regenass

15

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Guenter Dollenmaier

16

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Hans Hirsch

17

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Meri Gorgiewski

19

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Marc Bourlière

20

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Ioannis Theodorou

22

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Francesco Negro

26

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Swiss Hepatitis C Cohort Study Group

27

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

ANRS HC EP 26 Genoscan Study Group

28

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

language of work or name

0 references

publication date

16 December 2011

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

55

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

384-394

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

EASL Clinical Practice Guidelines: Management of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

What are the comorbidities influencing the management of patients and the response to therapy in chronic hepatitis C?

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

Pegylated-interferon plus ribavirin therapy in the treatment of CHC: individualization of treatment duration according to on-treatment virologic response

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

Lambda interferon inhibits hepatitis B and C virus replication

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

IL-28B/IFN-lambda 3 drives granzyme B loading and significantly increases CTL killing activity in macaques

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project).

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

Review article: predicting response in hepatitis C virus therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

Cohort Profile: the Swiss Hepatitis C Cohort Study (SCCS).

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

Interferon gamma receptor 2 gene variants are associated with liver fibrosis in patients with chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

Viral genotype-specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

Genetic variation in the interleukin -28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

Intrahepatic and peripheral blood virus-specific cytotoxic T lymphocyte activity is associated with a response to combination IFN-alpha and ribavirin treatment among patients with chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

Phenotypic and functional characterization of intrahepatic T lymphocytes during chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

Fine characterization of intrahepatic NK cells expressing natural killer receptors in chronic hepatitis B and C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

Simultaneous evaluation of lymphocyte subpopulations in the liver and in peripheral blood mononuclear cells of HCV-infected patients: relationship with histological lesions

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

The presence of an intrahepatic cytotoxic T lymphocyte response is associated with low viral load in patients with chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

Antitumor activity of IFN-lambda in murine tumor models

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

Interferon-lambda induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces anti-tumour effects in combination with anti-cancer agents

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

Antitumor activity of type I and type III interferons in BNL hepatoma model

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: Role in the course of chronic viral hepatitis and the development of HCC

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

21 January 2018

In-situ immunophenotyping study of hepatic-infiltrating cytotoxic cells in chronic active hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24678

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HEP.24678

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43047523&oldid=1978753862"